European position paper on rhinosinusitis and nasal polyps.

Rhinology. Supplement, 2005

2,294 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/34ff5a6d6da9e5cea0e30d0fef3bc760dd1df110

Citations in the corpus

• European Position Paper on Rhinosinusitis and Nasal Polyps 2020. (2020, background): “recent retrospective analysis from Finland suggests that some 15% of ARS may be odontogenic in nature((63)).”
• Bacterial Biofilm and its Role in the Pathogenesis of Disease (2020, background): “According to the duration of the disease, it can defined as acute when lasting less than 12 weeks, or chronic when lasting more than 12 weeks [151].”
• Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. (2016, background): “To determine which parameters were relevant in the generation of this diversity, principal component analysis and clustering of variables showed that diversity in our samples was driven by five groups of related cytokines: (1) markers of eosinophilic, Th2-driven inflammation and antibody production ”
• Position paper on olfactory dysfunction. (2017, background): “Recommendations: • Functional endoscopic surgery for olfactory loss caused by the CRS disease spectrum should be undertaken in line with existing guidelines (86).”
• Chronic rhinosinusitis in Europe – an underestimated disease. A GA2LEN study (2011, background): “The EP(3)OS group has proposed clear guidelines on the definition of rhinosinusitis that can be used for epidemiological and clinical research (9).”
• Clinical Practice Guideline (Update): Adult Sinusitis (2015, unknown): “This approach also differs from other guidelines and consensus statements that recommend antibiotics for patients with severe ABRS, manifesting as high fever and severe or worsening facial pain.(15,19,69)”
• IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. (2012, background): “In adults, the incidence is estimated to be 2–3 episodes per year [11].”
• Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. (2016, methodology): “Patients with CRSwNP and comorbid asthma (30% of patients with CRSwNP) have a characteristic poor therapeutic response and a high recurrence rate and their disease tends to be more resitant (1) (2).”
• Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study (2015, methodology): “In the United States and Europe, CRS is usually classified based on the presence or absence of nasal polyps: chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP) (1).”